<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39281184</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2689-2820</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Palliative medicine reports</Title><ISOAbbreviation>Palliat Med Rep</ISOAbbreviation></Journal><ArticleTitle>Feasibility and Safety of Food Containing <i>Acanthopanax</i> <i>senticosus</i> for Treating Patients with Cancer-Related Fatigue.</ArticleTitle><Pagination><StartPage>381</StartPage><EndPage>386</EndPage><MedlinePgn>381-386</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/pmr.2024.0041</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Cancer-related fatigue (CRF) is a major obstacle to quality of life. <i>Acanthopanax senticosus</i> Harms (ASH) is available as a botanical adaptogen food worldwide.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to assess the feasibility and safety of ASH in patients with CRF.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Fifteen patients with CRF consumed ASH drink for 28 days. The primary endpoint was the completion rate of the study, and the secondary endpoints were changes in brief fatigue inventory (BFI), oxidative stress markers, and adverse events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Seven patients successfully completed the study. Four patients who had BFI &lt;5.5 at enrollment revealed a decrease in BFI. The biological antioxidant potential/diacron-reactive oxygen metabolites ratio, potential antioxidant capacity, was increased but not significant (<i>p</i> = 0.063). No adverse events attributable to ASH were observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Approximately 50% patients were successful in consuming ASH for 28 days. Patients with mild CRF showed improvement by using ASH. However, further investigations are needed to validate these findings.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Mary Ann Liebert, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2256-0776</Identifier><AffiliationInfo><Affiliation>Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Nanae</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Higashi Sapporo Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Higashi Sapporo Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmura</LastName><ForeName>Tousei</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Higashi Sapporo Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihara</LastName><ForeName>Hiroyoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Higashi Sapporo Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Higashi Sapporo Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Maki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Science, School of Medical Technology, Health Sciences University of Hokkaido, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomonari</LastName><ForeName>Tetsu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Hidekatsu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Sapporo Medical University School of Medicine, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takayama</LastName><ForeName>Tetsuji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Palliat Med Rep</MedlineTA><NlmUniqueID>101770666</NlmUniqueID><ISSNLinking>2689-2820</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acanthopanax senticosus Harms</Keyword><Keyword MajorTopicYN="N">adaptogen</Keyword><Keyword MajorTopicYN="N">cancer-related fatigue</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39281184</ArticleId><ArticleId IdType="pmc">PMC11392680</ArticleId><ArticleId IdType="doi">10.1089/pmr.2024.0041</ArticleId><ArticleId IdType="pii">10.1089/pmr.2024.0041</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Anonymous. Foundation for Promotion of Cancer Research Japan (FPCRJ) cancer statistics in Japan–2023. 2024. Available from: https://ganjoho.jp/public/qa_links/report/statistics/ 2023_en.html [Last accessed: July
10, 2023].</Citation></Reference><Reference><Citation>Mock V, Atkinson A, Barsevick A, et al. . NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 2000;14(11A):151–161.</Citation><ArticleIdList><ArticleId IdType="pubmed">11195408</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Maqbali M, Al Sinani M, Al Naamani Z, et al. . Prevalence of fatigue in patients with cancer: A systematic review and meta-analysis. J Pain Symptom Manage 2021;61(1):167–189.e14; doi: 10.1016/j.jpainsymman.2020.07.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2020.07.037</ArticleId><ArticleId IdType="pubmed">32768552</ArticleId></ArticleIdList></Reference><Reference><Citation>Vio MT, Milan I, Tirelli U. Cancer-related fatigue (Review). Int J Oncol 2002;21:1093–1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370760</ArticleId></ArticleIdList></Reference><Reference><Citation>Bower JE, Bak K, Berger A, et al. . Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014;32(17):1840–1850; doi: 10.1200/JCO.2013.53.4495</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.53.4495</ArticleId><ArticleId IdType="pmc">PMC4039870</ArticleId><ArticleId IdType="pubmed">24733803</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen Ø, Laird B, Aass N, et al. . The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer. PLoS One 2017;12(5):e0177620; doi: 10.1371/journal.pone.0177620</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177620</ArticleId><ArticleId IdType="pmc">PMC5444654</ArticleId><ArticleId IdType="pubmed">28542626</ArticleId></ArticleIdList></Reference><Reference><Citation>Repka CP, Hayward R. Effects of an exercise intervention on cancer-related fatigue and its relationship to markers of oxidative stress. Integr Cancer Ther 2018;17(2):503–510; doi: 10.1177/1534735418766402</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1534735418766402</ArticleId><ArticleId IdType="pmc">PMC6041925</ArticleId><ArticleId IdType="pubmed">29649913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. . Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013;31(25):3076–3082; doi: 10.1200/JCO.2012.44.4661</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2012.44.4661</ArticleId><ArticleId IdType="pubmed">23897970</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong JS, Ryu BH, Kim JS, et al. . Bojungikki-tang for cancer-related fatigue: A pilot randomized clinical trial. Integr Cancer Ther 2010;9(4):331–338; doi: 10.1177/1534735410383170</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1534735410383170</ArticleId><ArticleId IdType="pubmed">21059621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mücke M, Cuhls H, Peuckmann-Post V, et al. . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2015;2015(5):CD006788–1858; doi: 10.1002/14651858.CD006788.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006788.pub3</ArticleId><ArticleId IdType="pmc">PMC6483317</ArticleId><ArticleId IdType="pubmed">26026155</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KY, Wu YC, Liu IM, et al. . Release of acetylcholine by Syringin, an active principle of Eleutherococcus senticosus, to raise insulin secretion in Wistar rats. Neurosci Lett 2008;434(2):195–199; doi: 10.1016/j.neulet.2008.01.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.01.054</ArticleId><ArticleId IdType="pubmed">18304730</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi JM, Hong SH, Kim JH, et al. . Effect of Acanthopanax senticosus stem on mast cell-dependent anaphylaxis. J Ethnopharmacol 2002;79(3):347–352; doi: 10.1016/S0378-8741(01)00403-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-8741(01)00403-2</ArticleId><ArticleId IdType="pubmed">11849840</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujikawa T, Yamaguchi A, Morita I, et al. . Protective effects of Acanthopanax senticosus Harms from Hokkaido and its components on gastric ulcer in restrained cold water stressed rats. Biol Pharm Bull 1996;19(9):1227–1230; doi: 10.1248/bpb.19.1227</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.19.1227</ArticleId><ArticleId IdType="pubmed">8889047</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Min Li X, Zhao Zhang S, et al. . Acanthopanax senticosus protects structure and function of mesencephalic mitochondria in a mouse model of Parkinson’s disease. Chin J Integr Med 2018;24(11):835–843; doi: 10.1007/s11655-018-2935-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-018-2935-5</ArticleId><ArticleId IdType="pubmed">30090975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano Y, Tanaka M, Fujishima M, et al. . Acanthopanax senticosus Harms extract causes G0/G1 cell cycle arrest and autophagy via inhibition of Rubicon in human liver cancer cells. Oncol Rep 2021;45(3):1193–1201; doi: 10.3892/or.2021.7948</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2021.7948</ArticleId><ArticleId IdType="pmc">PMC7859978</ArticleId><ArticleId IdType="pubmed">33650674</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Tanaka M, Murai R, et al. . Prophylactic and therapeutic effects of Acanthopanax senticosus Harms extract on murine collagen-induced arthritis. Phytother Res 2014;28(10):1513–1519; doi: 10.1002/ptr.5157</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.5157</ArticleId><ArticleId IdType="pmc">PMC4235467</ArticleId><ArticleId IdType="pubmed">24797499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sánchez-Rodríguez MA, Mendoza-Núñez VM. Oxidative stress indexes for diagnosis of health or disease in humans. Oxid Med Cell Longev 2019;2019:4128152; doi: 10.1155/2019/4128152</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/4128152</ArticleId><ArticleId IdType="pmc">PMC6899293</ArticleId><ArticleId IdType="pubmed">31885788</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda S, Nojima J, Motoki Y, et al. . A potential biomarker for fatigue: Oxidative stress and anti-oxidative activity. Biol Psychol 2016;118:88–93; doi: 10.1016/j.biopsycho.2016.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsycho.2016.05.005</ArticleId><ArticleId IdType="pubmed">27224647</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz AL, Meek PM, Nail LM, et al. . Measurement of fatigue determining minimally important clinical differences. J Clin Epidemiol 2002;55(3):239–244; doi: 10.1016/s0895-4356(01)00469-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-4356(01)00469-3</ArticleId><ArticleId IdType="pubmed">11864794</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>